A Phase 3, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Latest Information Update: 30 Apr 2025
At a glance
- Drugs Icotrokinra (Primary)
- Indications Erythrodermic psoriasis; Pustular psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
Most Recent Events
- 01 Apr 2025 Planned primary completion date changed from 19 Feb 2025 to 15 Apr 2025.
- 07 Nov 2024 According to a Protagonist Therapeutics media release, top line results for the Phase 3 in pustular and erythrodermic psoriasis is expected in Q2 2025.
- 09 Oct 2024 Status changed from recruiting to active, no longer recruiting.